RANDOMIZED, PROSPECTIVE STUDY OF T3 ON THE INCIDENCE OF POSTOPERATIVE ATRIAL

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。该项目的目的是观察心脏直视手术后使用一种名为三碘甲状腺原氨酸或T3的甲状腺激素治疗是否能降低发生房颤的风险。一些接受心内直视手术的患者可能会在术后期间发生心房颤动。房颤是一种心律失常，也是最常见的术后并发症。先前的研究表明，甲状腺激素可能会降低发生心房颤动的风险，并减少额外治疗的需要。这种药物可能会在脱离心内直视手术中使用的心肺机后使心跳变得更强。如果心脏跳动更强烈，可能根本不需要其他心脏支持药物，或者可能需要较短的持续时间和/或较低的浓度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this project is to see whether treatment with a thyroid hormone, called triiodothyronine or T3, following open heart surgery reduces the risk of developing atrial fibrillation. Some patients who undergo open heart surgery may develop atrial fibrillation in the post-operative period. Atrial fibrillation is an arrhythmia of the heart and is the most common post-operative complication. Prior studies have suggested that thyroid hormone may reduce the risk of developing atrial fibrillation and the need for additional treatment. The medication may make the heart beat stronger after coming off the heart lung machine, which is used during open heart surgery. If the heart beats stronger, other heart support medications may not be required at all or may be required for a shorter duration and/or at lower concentrations.